Premas Biotech and Oravax enter into licensing deal for commercialization of VLP injectable vaccine technology in India

Recently, Oravax Medical Inc., (“Oravax” has entered into a licensing agreement with Premas Biotech to make available for commercialization of Oravax’s virus-like particle (VLP) vaccine technology. Oravax is a joint venture between Oramed Pharmaceuticals Inc., a US-based company (the majority shareholder), and Gurugram, India-based life sciences company, Premas Biotech (“Premas”). While the terms of the license agreement have not been disclosed, Oravax will be entitled to royalties upon commercialization of this vaccine in India.

vaccinePremas Biotech has developed a triple antigen Covid-19 vaccine candidate that targets three SARS CoV-2 virus surface proteins. The vaccine candidate has been developed by Premas’ proprietary difficult-to-express proteins platform, D-CryptTM, which is believed to target proteins less susceptible to mutation, thus making the vaccine potentially more effective over other existing technologies against various variants of the COVID-19 virus. Premas have cloned, expressed, and purified all the variants of spike protein along with the N, M, and E proteins, that form an array of very high-quality antigens for diagnostics development. Oravax on the other hand combines technology acquired from its parents: Premas Biotech and protein oral delivery (POD™) oral delivery technology of Oramed Pharmaceuticals.

Under this agreement, Oravax has out-licensed certain rights in the territory of India to Premas Biotech. The VLP platform technology can be delivered either via injection or orally, and under this license agreement, Oravax has licensed to Premas the right to develop an injectable version of its VLP technology with an aim to address the urgent need for a vaccine that is effective against the Delta variant. Premas plans to manufacture, test, and potentially commercialize the injectable version of the VLP vaccine in India.

The VLP vaccine is being tested in preclinical studies against COVID-19 variants including the Delta variant. The VLP vaccine technology is highly scalable with a low cost of goods and easily transferable. The oral VLP COVID-19 vaccine is being developed for use both as a standalone vaccine as well as a booster for people who have been previously vaccinated for COVID-19.

Author: Arindam Purkayastha, a Patent Attorney at IIPRD, in case of any queries please contact/write back to us at arindam@iiprd.com.

Leave a Reply

Your email address will not be published. Required fields are marked *

1 × 4 =

Archives

  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • September 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010